

## Disclosures

### Personal Commercial (25)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Aegerion	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Alnylam	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Amarin	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Amgen	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Amgen	Research/Research Grants ‡ To Be Announced	Significant (>= \$5,000)	Prevention
Applied Therapeutics	Data Safety Monitoring Board	Modest (< \$5,000)	General Cardiology
Ascendia	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Better Therapeutics	Research/Research Grants	Significant (>= \$5,000)	Prevention
BMS	Research/Research Grants ‡ AEIOU trial	Significant (>= \$5,000)	Arrhythmias and Clinical EP
BMS	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
Boehringer-Ingelheim	Consultant Fees/Honoraria	Significant (>= \$5,000)	General Cardiology
Boehringer-Ingelheim	Research/Research Grants ‡ RE-DUAL PCI	Significant (>= \$5,000)	General Cardiology
Daiichi Sankyo	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Janssen Pharmaceuticals, Inc	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Janssen Pharmaceuticals, Inc	Research/Research Grants	Significant (>= \$5,000)	General Cardiology
Lexicon	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Merck	Consultant Fees/Honoraria	Significant (>= \$5,000)	Prevention
Merck	Research/Research Grants ‡ IMPROVE IT, and REVEAL	Significant (>= \$5,000)	Prevention
Novo Nordisk Inc.	Data Safety Monitoring Board	Significant (>= \$5,000)	Prevention
Novo Nordisk Inc.	Research/Research Grants	Significant (>= \$5,000)	Prevention
Pfizer	Research/Research Grants	Significant (>= \$5,000)	Prevention
Pfizer	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology
RhoShan	Consultant Fees/Honoraria	Modest (< \$5,000)	Acute Coronary Syndromes
Sanofi-Aventis	Consultant Fees/Honoraria	Significant (>= \$5,000)	Acute Coronary Syndromes Prevention

### Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

### Personal Organizational or Other Non-Commercial (0)

No disclosures on record

### Clinical Trial Enroller (0)

No disclosures on record

## Institutional Financial Decision-Making Role (0)

No disclosures on record

## Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

## Agreement

---

### Certified Education Attestation | Signed on 9/19/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>*

### Confidentiality, Disclosure and Assignment Agreement | Signed on 9/19/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>*

### Embargo | Signed on 9/19/2024

*URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>*

### On-Going Obligation Agreement | Signed on 9/19/2024

---

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.